TTK Healthcare break out

akashbothra Updated   
1. Buy or Sell at your own risk
2. Don't risk more than 1%-2% of your capital as stop loss
3. Position Size formula:- Stop Loss/(Buy Price-Initial Stop Loss Price)
4. Sell on initial stop loss hit or close below daily supertrend (for short term traders) or close below weekly supertrend (for long term investors)
5. Some other ways to sell stocks can be
a. 25% or 50% up in three weeks or less
b. Largest weekly price spread
c. Exhaustion gaps
d. Heavy daily volume without further upside
e. Largest one day price drop

after a quarter sales growth of 18%, quarter profit growth of 58%, TTM sales growth of 30% and TTM profit growth off 39%, TTKHLTCARE has given a high-volume breakout today after a consolidation since July 2021. One can buy with a stop at Rs. 798.

Other fundamentals: -
1. TTK Healthcare Ltd is engaged in the business of Pharmaceuticals, Consumer Products, Medical Devices, Protective Devices and Foods. It is a part of TT Krishnamachari group; whose flagship company, TTK Prestige Ltd is one of the leading kitchen appliances company in India.

2. The company's pharmaceuticals business include products for both human and veterinary use :-

a. Ethical Products/ Pharma Division - The company's ethical pharma business deals in pharmaceutical formulations both herbal and allopathic, in various therapeutic segments and food supplements. It has a network of 1000+ sales team and a network of 3000+ distributors.
b. Animal Welfare Division - The company sells a wide range of animal pharma products under this division. Its portfolio includes feed supplements, fertility inducers, antibiotics, cocktail enzymes, etc. Its network is spread over 9,000 veterinarians across India.

3. The company's consumer products business comprises of marketing and distribution of Woodward's Gripewater, EVA range of cosmetics, Good home range of scrubbers, air freshners, etc. The company's brand 'Woodward's Gripe Water' is one of the oldest FMCG brands worldwide and is a market leader in the Indian colic market. It has been marketed in India since 1928. Its distribution network includes 27 warehouses, 2,600+ distributors, 650+ frontline sales team and a reach to 4 lakh+ outlets across India.

4. The company is one of the largest manufacturers of extruded products (papad) in India which are B2B and export customers and are also marketed in selected markets in India. It sells its products under the brand name 'Fryums'.

5. Company is one of the key players in the Indian Condom Industry. It is involved in manufacture and marketing of male contraceptives and other allied products. It sells products under its own brand 'SKORE'.

6. The company's medical devices business is divided into 2 divisions :-

a. Orthopedics Division- The company's orthopedics division offers joint replacement portfolio which includes a variety of components, types and sizes. It has technical collaborations with various companies situated in USA, Germany, UK & Italy for the orthopedics business.
b. Heart Valve Division - The division manufactures and distributes heart valve prosthesis in India. It manufactures all 3 components for heart valve i.e. Frame, Disc & sewing ring. It has a manufacturing capacity of 20,000 heart valves p.a.

7. Presently, the company owns and operates 8 manufacturing facilities in India in Karnataka, Tamil Nadu, Puducherry, Kerala, and Rajasthan. It has adopted an outsourcing model for manufacturing most of its products, except for foods, medical and protective devices divisions.

8. Promoter Holding at 75% (greater than 45% is good)

9. Dividend Yield at 0.67% (consistent dividend payer since 2010)

10. Debt to equity at 0.02 (less than 1 is good), Interest Coverage at 17.3 (greater than 3 is good), Current ratio at 1.99% (greater than 1.5 is good), FCF to CFO at 59% (company won’t have to raise debt for expansion)
NEWS UPDATE: Advent backed homegrown private pharma company Bharat Serums & Vaccines buys Chennai-based TTK Healthcare's human pharma division for Rs 805 cr.
Trade closed: stop reached


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.